[go: up one dir, main page]

HK1207666A1 - Rnai pharmaceutical composition capable of suppressing expression of kras gene - Google Patents

Rnai pharmaceutical composition capable of suppressing expression of kras gene Download PDF

Info

Publication number
HK1207666A1
HK1207666A1 HK15108285.0A HK15108285A HK1207666A1 HK 1207666 A1 HK1207666 A1 HK 1207666A1 HK 15108285 A HK15108285 A HK 15108285A HK 1207666 A1 HK1207666 A1 HK 1207666A1
Authority
HK
Hong Kong
Prior art keywords
enyl
lipid
compound
nucleic acid
carbon number
Prior art date
Application number
HK15108285.0A
Other languages
English (en)
Chinese (zh)
Inventor
Tomoyuki Naoi
Takeshi Kuboyama
Junichi Enokizono
Toshihiko Ishii
Akihiro TOKUNAGA
Kentarou HATANAKA
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Dicerna Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd., Dicerna Pharmaceuticals, Inc. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of HK1207666A1 publication Critical patent/HK1207666A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15108285.0A 2012-07-16 2013-07-16 Rnai pharmaceutical composition capable of suppressing expression of kras gene HK1207666A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671963P 2012-07-16 2012-07-16
US61/671,963 2012-07-16
PCT/JP2013/069322 WO2014013995A1 (ja) 2012-07-16 2013-07-16 KRAS遺伝子発現抑制RNAi医薬組成物

Publications (1)

Publication Number Publication Date
HK1207666A1 true HK1207666A1 (en) 2016-02-05

Family

ID=49948821

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108285.0A HK1207666A1 (en) 2012-07-16 2013-07-16 Rnai pharmaceutical composition capable of suppressing expression of kras gene
HK15107660.7A HK1207113A1 (en) 2012-07-16 2013-07-16 Rnai pharmaceutical composition capable of suppressing expression of kras gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15107660.7A HK1207113A1 (en) 2012-07-16 2013-07-16 Rnai pharmaceutical composition capable of suppressing expression of kras gene

Country Status (10)

Country Link
US (1) US9913907B2 (ja)
EP (1) EP2873732A4 (ja)
JP (1) JP6272226B2 (ja)
CN (1) CN104471062A (ja)
AU (1) AU2013291125A1 (ja)
CA (1) CA2878314A1 (ja)
HK (2) HK1207666A1 (ja)
SG (1) SG11201502954TA (ja)
TW (1) TW201408324A (ja)
WO (1) WO2014013995A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104651362A (zh) * 2009-04-03 2015-05-27 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EP3153172A4 (en) * 2014-06-04 2018-01-17 Kyowa Hakko Kirin Co., Ltd. Ckap5-gene-silencing rnai pharmaceutical composition
AU2015285279A1 (en) 2014-06-30 2017-02-16 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
EA201991804A1 (ru) 2017-02-01 2020-02-07 МОДЕРНАТиЭкс, ИНК. ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ
EP3617314B1 (en) * 2017-04-28 2023-02-15 Kyowa Kirin Co., Ltd. Oligonucleotide derivative or salt thereof
AU2019226586B2 (en) * 2018-03-02 2024-08-29 Elicio Therapeutics, Inc. Compounds including a mutant KRAS sequence and a lipid and uses thereof
AU2020259449A1 (en) 2019-04-17 2021-12-09 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
CN111534520A (zh) * 2020-05-27 2020-08-14 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
ZA8681B (en) 1985-01-07 1987-08-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JP2923296B2 (ja) 1988-11-14 1999-07-26 株式会社ビタミン研究所 細胞への遺伝子導入法
JPH0696670B2 (ja) 1988-11-16 1994-11-30 日本ポリウレタン工業株式会社 反応性安定化ポリオール組成物
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP1027033B1 (en) 1997-05-14 2009-07-22 The University Of British Columbia High efficiency encapsulation of nucleic acids in lipid vesicles
TWI225412B (en) 1997-06-23 2004-12-21 Sequus Pharm Inc Liposome-entrapped polynucleotide composition and method
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US6656498B1 (en) * 1998-11-25 2003-12-02 Vanderbilt University Cationic liposomes for gene transfer
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
CN1284523C (zh) 2000-10-04 2006-11-15 协和发酵工业株式会社 由脂质膜被覆微粒的方法
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
DK1409506T3 (da) 2001-07-23 2012-08-06 Univ Leland Stanford Junior Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
KR20070104575A (ko) 2005-01-28 2007-10-26 교와 핫꼬 고교 가부시끼가이샤 표적 유전자의 발현을 억제하는 조성물
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
WO2008109516A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
US20110117125A1 (en) * 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
AU2009336191B2 (en) * 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
CN104651362A (zh) 2009-04-03 2015-05-27 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EP2567951B1 (en) 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
WO2013089151A1 (ja) * 2011-12-12 2013-06-20 協和発酵キリン株式会社 カチオン性脂質を含有するドラッグデリバリーシステムのための脂質ナノ粒子
KR20140111272A (ko) 2011-12-12 2014-09-18 교와 핫꼬 기린 가부시키가이샤 양이온성 지질의 조합을 함유하는 지질 나노 입자

Also Published As

Publication number Publication date
CN104471062A (zh) 2015-03-25
JP6272226B2 (ja) 2018-01-31
JPWO2014013995A1 (ja) 2016-07-07
TW201408324A (zh) 2014-03-01
EP2873732A1 (en) 2015-05-20
AU2013291125A1 (en) 2015-01-22
CA2878314A1 (en) 2014-01-23
EP2873732A4 (en) 2016-03-23
US20140044755A1 (en) 2014-02-13
SG11201502954TA (en) 2015-05-28
US9913907B2 (en) 2018-03-13
WO2014013995A1 (ja) 2014-01-23
HK1207113A1 (en) 2016-01-22

Similar Documents

Publication Publication Date Title
US9839616B2 (en) Lipid nano particles comprising cationic lipid for drug delivery system
CN104159615B (zh) 含有阳离子性脂质的组合的脂质纳米粒子
EP2871178B1 (en) Cationic lipid
US9913907B2 (en) RNAi pharmaceutical composition for suppressing expression of KRAS gene
EP3153172A1 (en) Ckap5-gene-silencing rnai pharmaceutical composition
KR20170023004A (ko) 양이온성 지질
JP2018065789A (ja) カチオン性脂質
JPWO2017111172A1 (ja) カチオン性脂質としての化合物
US20140294978A1 (en) Cationic lipid
WO2018225873A1 (ja) 核酸含有ナノ粒子